Elevated factor XI is associated with increased risk of recurrent cerebral venous sinus thrombosis: a cohort study
- PMID: 38145433
- PMCID: PMC10961281
- DOI: 10.1007/s11239-023-02935-2
Elevated factor XI is associated with increased risk of recurrent cerebral venous sinus thrombosis: a cohort study
Abstract
Cerebral venous sinus thrombosis (CVST) has no identified cause in 15% of cases. Elevated factors (F) VIII and FXI have been associated with thromboembolism, but data on CVST are limited. We hypothesized that elevated plasma FVIII and FXI predispose to first and recurrent CVST. In 50 CVST survivors aged < 60 years, following anticoagulant cessation and in 50 controls, we determined plasma FVIII and FXI, along with fibrin clot properties: lysis time, permeability, maximum D-dimer (D-Dmax), and maximum rate of D-dimer increase (D-Drate). We recorded CVST recurrence during a follow-up of 58.5 (55.0-60.0) months. Plasma FVIII was 22.7% higher in CVST than in controls, with elevated FVIII > 150% in 13 (26%) vs. 4 (8%) patients, respectively (p = 0.02). Median FXI tended to be higher in CVST vs. controls (110.5 [99.0-117-0]% vs. 104.5 [97.0-116.0]%, p = 0.07), while FXI > 120% was observed more commonly in the former group (12 [24%] vs. 4 [8%], respectively, p = 0.03). Patients with FVIII > 150% were less likely to achieve complete recanalization compared with the remainder (2 [15.4%] vs. 28 [75.7%], respectively; p < 0.001). Eight patients (16%) experienced CVST recurrence. They had higher baseline FXI, but not FVIII, as compared with the remainder (125.5 [114.5-140.0]% vs. 107.5 [102.0-117.0]%, respectively, p = 0.01). Patients with FXI > 120% were four times more likely to have recurrent CVST (5 [62.5%] vs. 7 [16.7%], respectively; p = 0.01). Plasma FXI > 120% could represent a novel risk factor for first and recurrent CVST. Given advances in anti-FXI agents, CVST might be another indication for this emerging treatment.
Keywords: Cerebral venous sinus thrombosis; Factor VIII; Factor XI; Stroke; Thrombosis.
© 2023. The Author(s).
Conflict of interest statement
The authors have no conflict of interest to report with regard to this study.
Figures
Similar articles
-
Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties.J Thromb Thrombolysis. 2019 Jan;47(1):8-15. doi: 10.1007/s11239-018-1769-0. J Thromb Thrombolysis. 2019. PMID: 30511257 Free PMC article.
-
Altered Fibrin Clot Properties in Patients With Cerebral Venous Sinus Thrombosis: Association With the Risk of Recurrence.Stroke. 2015 Sep;46(9):2665-8. doi: 10.1161/STROKEAHA.115.009528. Epub 2015 Jul 14. Stroke. 2015. PMID: 26173730
-
Effect of high-dose statin therapy on coagulation factors: Lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease.Vascul Pharmacol. 2023 Apr;149:107153. doi: 10.1016/j.vph.2023.107153. Epub 2023 Feb 11. Vascul Pharmacol. 2023. PMID: 36774992
-
Coagulation factor XI as a novel target for antithrombotic treatment.J Thromb Haemost. 2010 Nov;8(11):2349-57. doi: 10.1111/j.1538-7836.2010.04031.x. J Thromb Haemost. 2010. PMID: 20727068 Review.
-
Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review.J Prim Care Community Health. 2022 Jan-Dec;13:21501319221074450. doi: 10.1177/21501319221074450. J Prim Care Community Health. 2022. PMID: 35142234 Free PMC article.
Cited by
-
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism.Nat Rev Cardiol. 2025 Mar 31. doi: 10.1038/s41569-025-01144-z. Online ahead of print. Nat Rev Cardiol. 2025. PMID: 40164778 Review.
-
Factor XI and Atrial Fibrillation: A Mismatched Pairing?Eur Cardiol. 2025 Apr 10;20:e08. doi: 10.15420/ecr.2024.61. eCollection 2025. Eur Cardiol. 2025. PMID: 40309219 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources